{"id":"NCT01143090","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","officialTitle":"A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2011-11","completion":null,"firstPosted":"2010-06-14","resultsPosted":"2012-12-17","lastUpdate":"2015-06-12"},"enrollment":149,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Schizoaffective Disorder"],"interventions":[{"type":"DRUG","name":"Lurasidone HCl","otherNames":[]}],"arms":[{"label":"Open Label","type":"EXPERIMENTAL"}],"summary":"Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).","primaryOutcome":{"measure":"Adverse Events","timeFrame":"6 months","effectByArm":[{"arm":"Lurasidone Overall","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["24330868","27245981"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":148},"commonTop":["Nausea","Insomnia","Akathisia","Anxiety"]}}